Kenai Therapeutics announces USD 82Mln series A financing
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. […]
Bristol Myers Squibb acquires Karuna Therapeutics
Bristol Myers Squibb and Karuna Therapeutics, Inc. recently announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved […]
Pharmanovia acquires Global CNS Portfolio From Sanofi
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, recently announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. The brands span four therapy areas of ongoing unmet need associated with CNS […]
Eisai Updates On Long Term Outcomes of Investigational Aβ protofibril antibody lecanemab
Eisai Co., Ltd. announced that an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody lecanemab in people living with early Alzheimer’s disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy. In this simulation, lecanemab treatment is estimated to potentially slow the rate of disease progression, maintaining treated […]
